Biostatistics/Bioinformatics Core

生物统计学/生物信息学核心

• 批准号: 8379509
• 负责人: Li-Xuan Qin
• 金额: $ 9.61万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8379509
• 关键词: Address; Bioinformatics; Biometry; Clinical Research; Clinical Trials; Clinical Trials Design; Cox Proportional Hazards Models; DNA copy number; Data; Data Analyses; Drug Formulations; Experimental Designs; Genetic Transcription; Genomics; Human; Laboratories; Laboratory Research; Memorial Sloan-Kettering Cancer Center; Messenger RNA; Methodology; Methods; MicroRNAs; Molecular; Molecular Profiling; Mutation; Outcome; Pathway Analysis; Pathway interactions; Pharmaceutical Preparations; Phase; Phenotype; Population; Principal Investigator; Procedures; Protocols documentation; Randomized; Research; Research Personnel; Risk; Sample Size; Sampling; Testing; anticancer research; base; design; member; molecular scale; preclinical study; primary outcome; research study; sarcoma; soft tissue; tool; tumor; tumorigenesis

The Biostatistics & Bioinformatics Core will support investigators of the SPORE in Soft Tissue Sarcoma in the computational and statistical aspects of their research efforts, including the design and analysis of clinical trials, laboratory experiments, molecular profiling, and sequencing, as well as integrated genomic analyses. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this review, a statistical section for the protocol will be provided, outlining major scientific objecfives, population to be studied, primary and secondary endpoints, experimental design, analysis plans, and a targeted sample size justified in probabilisfic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol. In preclinical studies, core members will assist in the formulation of the experimental design and in the analysis and interpretafion of the data at the conclusion of the study. The core will also assist in the large-scale molecular characterizafion of human sarcoma samples, which involves analyzing RNA expression, microRNA expression, mutafions, and DNA copy number changes to identify predictors of tumor characterisfics, drug repsonse, and survival. Core members will use two-sample t-tests and Cox proportional hazards models to identify informafive features. The different types of molecular data will be integrated and pathway analysis performed to elucidate the pathways that contribute to tumorigenesis and tumor phenotype. Risk predicfion tools will be developed using Cox proportional hazards models based on these features

生物统计学和生物信息学核心将支持软组织肉瘤 SPORE 的研究人员 他们的研究工作的计算和统计方面，包括临床研究的设计和分析 试验、实验室实验、分子分析和测序以及综合基因组分析。 在临床试验设计阶段，核心成员将与主要研究者一起进行方案审查。 根据本次审查，将提供该方案的统计部分，概述主要科学 目标、要研究的人群、主要和次要终点、实验设计、分析计划、 以及从概率角度证明合理的目标样本量。试验结束时，将进行数据分析 旨在评估方案中规定的主要和次要终点的结果。在临床前 研究中，核心成员将协助制定实验设计并进行分析和研究 研究结束时对数据的解释。该核心还将协助大规模分子 人类肉瘤样本的表征，包括分析 RNA 表达、microRNA 表达、突变和 DNA 拷贝数变化，以确定肿瘤特征、药物的预测因子 反应和生存。核心成员将使用双样本 t 检验和 Cox 比例风险模型来 识别信息特征。不同类型的分子数据将被整合并进行通路分析 旨在阐明有助于肿瘤发生和肿瘤表型的途径。风险预测 将使用基于这些特征的 Cox 比例风险模型来开发工具